Tag Archives: Emerging Companies

2012 BIO Investor Forum: Looking Ahead to Investment Opportunities

partnering1

The biggest biotech news out of Washington in recent months was the Jumpstart Our Business Startups (JOBS) Act, which passed Congress overwhelmingly and was signed into law by President Obama in April.  For those not familiar, the JOBS Act creates a new category of issuers, called “emerging growth companies” (EGCs), which is defined as newly public companies with than $1 billion in annual revenues and a public float below $700 million. EGCs are given a Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

2012 BIO International Convention: Q&A with Progenika

Progenika

In anticipation of the 2012 BIO International Convention we spoke with Progenika, a newly established Spanish healthcare company, to get their perspective on the event. Progenika develops, produces, and commercializes tools for the diagnosis and prognosis of diseases and for predicting response to drug treatment. Read on to learn more about this innovative company. 1) Progenika is a newly established company that has created new subsidiaries; it has internationalized and brought products to the market Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO CEO Company Snapshot: NuPathe Inc.

NuPathe

The Company Snapshots have returned for our next One-on-One Partnering event, the BIO CEO & Investor Conference, taking place in New York City this February.  The companies that will be profiled in these snapshots will all be presenting at the event, and we hope this provides the opportunity to learn more about them, and catch up on what’s new. For our first Snapshot for the BIO CEO event, we’ve spoken with NuPathe Inc. about their Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

Drug Discovery & Development: Partnering for Success…and Survival

There are pressures on Big Pharma and biotech emerging companies alike to engage in more creative deal making to ensure positive outcomes for both parties, Ted Agres writes in Drug Discovery and Development. While the number of deals has remained relatively flat in 2011, the dollar amount of individual deals has increased overall. Oncology remains the most sought after category, followed by CNS, anti-infectives, metabolic diseases, dermatology and cardiovascular. Partnering activity at BIO events is on Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,

The Critical Importance of International Patent Protection for Small Businesses

Stanley Erck

As part of the implementation of the Leahy-Smith America Invents Act, the U.S. Patent and Trademark Office (PTO) recently held two public hearing on international patent protection.  Stanley C. Erck, President and CEO of Novavax, Inc., testified on behalf of BIO in support of an initiative to reduce filing and prosecution costs for international patent protection of biotech inventions. In his testimony, Mr. Erck explained the important role patents play in the biotechnology industry. The Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,